Biosimilars Action Plan

To encourage innovation and competition in the market for biological products and facilitate the development of biosimilars and interchangeable biosimilars, FDA has developed the Biosimilars Action Plan (BAP). The plan outlines the Agency’s commitments and focuses on...

Bulk Drug Substances

Compounders sometimes prepare drugs using bulk drug substances, also known as active pharmaceutical ingredients. For example, when a patient has an allergy to an ingredient in an FDA-approved drug, a state-licensed pharmacist or physician, or an outsourcing facility,...